Nuclear Medicine Market Report 2026

The nuclear medicine market size has grown rapidly in recent years. It will grow from $10.18 billion in 2025 to $11.4 billion in 2026 at a compound annual growth rate (CAGR) of 11.9%. The growth in the historic period can be attributed to limited access to nuclear imaging equipment, high cost of radiopharmaceuticals, lack of trained personnel, limited hospital and diagnostic center infrastructure, low patient awareness.

The nuclear medicine market size is expected to see rapid growth in the next few years. It will grow to $17.13 billion in 2030 at a compound annual growth rate (CAGR) of 10.7%. The growth in the forecast period can be attributed to rising demand for advanced diagnostic and therapeutic procedures, increasing government initiatives for cancer and cardiac care, growth in hospital and diagnostic center adoption, technological advancements in radiopharmaceuticals and imaging, increasing patient awareness and healthcare expenditure. Major trends in the forecast period include rising adoption of diagnostic imaging techniques, increasing use of therapeutic radiopharmaceuticals, growing demand for pet and spect scans, rising focus on oncology and cardiology applications, increasing implementation in hospitals and diagnostic centers.

The rising prevalence of cardiovascular disease (CVD) and cancer is expected to drive the growth of the nuclear medicine market in the coming years. Cardiovascular diseases encompass a range of disorders affecting the heart and blood vessels, while cancer involves uncontrolled cell growth that can spread to other parts of the body. Nuclear medicine plays a key role in both diagnosis and treatment: nuclear cardiac imaging enables earlier detection of heart conditions, and nuclear medicine therapies provide targeted treatment for cancer, often complementing surgery or chemotherapy. For instance, in January 2023, the American Cancer Society Inc., a US-based non-profit organization, reported that 1,958,310 new cancer cases were expected in the US, up from 1,918,030 in 2022. Therefore, the rising prevalence of cardiovascular diseases and cancer is fueling demand for nuclear medicine solutions.

Major companies in the nuclear medicine market are developing innovative technologies, such as nuclear medicine cyclotrons, to improve radiopharmaceutical production and diagnostic imaging capabilities. Nuclear medicine cyclotrons are specialized particle accelerators that generate radioactive isotopes by directing high-energy particles at target materials, enabling the synthesis of radiopharmaceuticals used in procedures like positron emission tomography (PET). For example, in January 2024, GE Healthcare China, a US-based medical technology company, launched its first batch of cyclotrons at Chengdu Tianfu International Bio-Town. These advanced accelerators support the production of medical isotopes for molecular imaging and therapeutic applications, establishing an ecosystem for early disease detection and personalized treatment.

In December 2023, Bristol Myers Squibb, a US-based biopharmaceutical company, acquired RayzeBio, Inc. for approximately $4.1 billion to strengthen its oncology radiopharmaceutical portfolio. This acquisition enables BMS to integrate RayzeBio’s actinium-based targeted radiopharmaceutical platform and advance the development of first-in-class therapies for solid tumors. RayzeBio, Inc., a US-based clinical-stage company, specializes in targeted radiopharmaceutical therapeutics, positioning BMS to expand its offerings in precision oncology.

Major companies operating in the nuclear medicine market are Bracco Imaging S.P.A., Lantheus Medical Imaging Inc., NTP Radioisotopes SOC Ltd., Eckert & Ziegler Group, Jubilant Pharma LLC, Australian Nuclear Science & Technology Organisation, Cardinal Health Inc., GE Healthcare Technologies Inc., Curium Pharma, Advanced Accelerator Applications USA Inc., Nordion Inc., The Institute for Radioelements, Eczacibasi-Monrol Nuclear Products Co., Siemens Healthineers AG, Cambridge Isotope Laboratories Inc., Bayer AG, Triad Isotopes Inc., Mallinckrodt Pharmaceuticals plc, PharmaLogic Holdings Corp., Institute of Isotopes Co. Ltd., Sinotau Pharmaceuticals Limited, Isotopia Molecular Imaging Limited, SHINE Medical Technologies Inc., JSC Isotope Inc., NorthStar Medical Radioisotopes LLC, Global Medical Solutions LLC.

North America was the largest region in the nuclear medicine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the nuclear medicine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the nuclear medicine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the nuclear medicine market by increasing the cost of imported radiopharmaceuticals, imaging equipment, and diagnostic tools, impacting hospitals and diagnostic centers in regions such as north america, europe, and asia-pacific. These costs can slow adoption of advanced PET, SPECT, and therapeutic applications. However, tariffs also drive local manufacturing and production of radiopharmaceuticals, promoting domestic supply chains and innovation in cost-efficient imaging and therapy solutions.

The nuclear medicine market research report is one of a series of new reports that provides nuclear medicine market statistics, including nuclear medicine industry global market size, regional shares, competitors with a nuclear medicine market share, detailed nuclear medicine market segments, market trends and opportunities, and any further data you may need to thrive in the nuclear medicine industry. This nuclear medicine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Nuclear medicine is a specialized branch of radiology that uses radioactive materials within the body to assess a patient’s overall health and detect medical conditions.

The primary types of nuclear medicine are diagnostic and therapeutic. Diagnostic procedures are conducted to identify specific areas of strength or weakness in the body, helping to detect conditions, diseases, or illnesses. Applications of nuclear medicine include cardiology, lymphoma, thyroid disorders, neurology, oncology, and others. End users include hospitals and clinics, diagnostic centers, and additional healthcare facilities.

The nuclear medicine market consists of sales of bone density scanning, cardiac PET perfusion, cardiac PET sarcoid. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.